Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

RYZ401

Phase 1Small molecule

RRayzeBio, Inc.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

GEP-NETRecruiting

GEP-NETPhase 1

Recruiting

Timeline

Expected Milestones

Q2 2033

Phase 1Recruiting

GEP-NET

NCT07165132

Clinical

Trials by Indication[1]

GEP-NET1 trial

Phase 1 First-in-Human, Dose Escalation and Dose Expansion Study of RYZ401, a Novel Radiopharmaceutical Therapy Labeled With Actinium-225, in Subjects With Neuroendocrine Tumors and Other Solid Tumors Expressing Somatostatin Receptors.

Recruiting·RRayzeBio, Inc.·Phase 1·NCT07165132·104 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for RYZ401. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RYZ401 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RYZ401. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — RayzeBio, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: RRayzeBio, Inc.

Related News